MM McGregor, P Olliaro, L Wolmarans, B Mabuza, M Bredell, MK Felten and PB Fourie
MRC National Tuberculosis Research Programme, Pretoria, South Africa.

The efficacy and safety of rifabutin (RBT) and rifampicin (RMP) were compared in 298 patients with newly diagnosed pulmonary tuberculosis. In the initial 8-wk phase, all patients received isoniazid 400 mg/d, ethambutol 1200 mg/d, and pyrazinamide 2 g/d and were randomly allocated to receive either RMP 600 mg/d or RBT 300 mg/d. In the 16-wk continuation phase, patients received intermittent treatment (twice weekly) with isoniazid 600 mg/d, ethambutol 2400 mg/d and either RMP 600 mg/d or RBT 300 mg/d. Two hundred twenty-five (RMP = 118; RBT = 107) patients completed the 24-wk treatment period (evaluable patient population). Bacteriologic conversion rates in the RMP and RBT groups were 87.7 versus 92.0% at Week 8, 99.1 versus 99.0% at Week 12, 93.5 versus 93.8% at Week 24, and 89.8 versus 95.3% at the last valid observation. The mean time to first bacteriologic conversion was 14.1 wk in the RMP group and 14.3 wk in the RBT group. None of these differences was significant. Adverse events were reported by four patients (five events) in the RMP group and six patients (six events) in the RBT group. Those events thought to be associated with RMP were increased SGOT and leucopenia and, with RBT, increased SGOT and thrombocytopenia. Two hundred four patients entered the follow-up phase, and, of these, 95 (RMP = 49; RBT = 46) completed the scheduled 24-mo period. The overall rate of relapse was 3.8% (4/106) for the RMP group and 5.1% (5/98) for the RBT group. These differences were not significant. All relapsed patients, except for two who could not be traced, were successfully retreated. We conclude that the efficacy and tolerability of RBT is equivalent to that of RMP in the treatment of newly diagnosed uncomplicated tuberculosis, and that RBT can be effectively administered in a part-daily, part-intermittent dosage schedule.

This article has been cited by other articles:

				W. Burman, D. Benator, A. Vernon, A. Khan, B. Jones, C. Silva, C. Lahart, S. Weis, B. King, B. Mangura, et al. Acquired Rifamycin Resistance with Twice-Weekly Treatment of HIV-related Tuberculosis Am. J. Respir. Crit. Care Med., February 1, 2006; 173(3): 350 - 356. [Abstract] [Full Text] [PDF]

				P. Cahn, H. Perez, G. Ben, and C. Ochoa Tuberculosis and HIV: A Partnership Against the Most Vulnerable J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2003; 2(3): 106 - 123. [Abstract] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 603 - 662. [Full Text] [PDF]

				M.D. Iseman Tuberculosis therapy: past, present and future Eur. Respir. J., July 1, 2002; 20(36_suppl): 87S - 94s. [Abstract] [Full Text] [PDF]

				W. J. BURMAN and B. E. JONES Treatment of HIV-related Tuberculosis in the Era of Effective Antiretroviral Therapy Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 7 - 12. [Abstract] [Full Text] [PDF]

				N. Rastogi, K. S. Goh, M. Berchel, and A. Bryskier Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG J. Antimicrob. Chemother., October 1, 2000; 46(4): 565 - 570. [Abstract] [Full Text] [PDF]

				Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247. [Full Text] [PDF]

				C MAYAUD and J CADRANEL Tuberculosis in AIDS: past or new problems? Thorax, July 1, 1999; 54(7): 567 - 571. [Full Text]

				D. V. Havlir and P. F. Barnes Tuberculosis in Patients with Human Immunodeficiency Virus Infection N. Engl. J. Med., February 4, 1999; 340(5): 367 - 373. [Full Text] [PDF]

				Joint Tuberculosis Committee of the British Thorac Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998 Thorax, July 1, 1998; 53(7): 536 - 548. [Abstract] [Full Text]

				R. J. O'Brien and A. A. Vernon New Tuberculosis Drug Development . How Can We Do Better? Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1705 - 1707. [Full Text] [PDF]

				J. R. UNGO, D. JONES, D. ASHKIN, E. S. HOLLENDER, D. BERNSTEIN, A. P. ALBANESE, and A. E. PITCHENIK Antituberculosis Drug-induced Hepatotoxicity . The Role of Hepatitis C Virus and the Human Immunodeficiency Virus Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1871 - 1876. [Abstract] [Full Text] [PDF]

				Treating Concurrent HIV and TB: A Clinical Alert from the CDC AIDS Clinical Care, December 1, 1996; 1996(1201): 1 - 1. [Full Text]